Important note: Information in this article was accurate in January 2009. The state of the art may have changed since the publication date.
Apricitabine 48 week results
HIV Treat Bull - 2009 Jan-Feb;10(1/2): 05
Simon Collins, HIV i-Base
Final 48 week results from a Phase 2b study of apricitabine (ATC), a new cytidine analogue similar to 3TC, in approximately 40 treatment-experienced patients with resistance to 3TC (at baseline, 52% of patients had ≥3 thymidine mutations and 76% had ≥1 non-NRTI mutation). At week 24 all patients switched to the higher dose 800mg ATC.
By week 48, around 90% patients achieved viral suppression <50 copies/mL in all arms. CD4 increases were ~ +260 cells/mm3 in the ATC arms vs +200 cells/mm3 in the 3TC arm. No significant ATC-related SAEs were reported.
Reference
Cahn P et al. 48-week data from Study AVX-201 - A randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. J Int AIDS Soc 2008, 11(Suppl 1):41 doi:10.1186/1758-2652-11-S1-O41.
2009-02-10
IB2009-01-05
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.